Publications

 
Contact Us
Investors / Media
William Duke, Jr.
781.357.2333
wduke@pulmatrix.com

As we advance our mission to develop breakthrough therapies that fundamentally change the way we treat, prevent, and control progressive and infectious respiratory diseases, we regularly share the progress of our research.

To learn more about our science and research findings, download the PDFs below:

RDD 2014 - Levofloxacin Dry Powders Engineered for Efficient Pulmonary Delivery and Stability / PDF
RDD 2012 — Development of an iSPERSE™ Based Platform for the Delivery of Macromolecules via Dry Powder Formulations / PDF
RDD 2012 — Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology / PDF
A Novel Inhaled Dry Powder Delivery Platform for the Delivery of Large Molecule Drugs to the Lung for Local and Systemic Treatments / PDF
RDD Europe 2011 - iSPERSE™: Formulation and In Vitro Characterization of a Novel Dry Powder Drug Delivery Technology / PDF
ATS 2011 — Efficacy of Fluticasone and Salmeterol in a Novel Inhaled Dry Powder Delivery Platform / PDF
ISAM 2011 Conference abstract — Deposition of Aerosolized Liquid Formulation in Ferrets by 3D CT / Spect Imaging / PDF
ISAM 2011 Conference abstract — A Novel Inhaled Dry Powder Delivery Platform; Efficacy of Fluticasone and Salmeterol During Allergic Asthm / PDF

print email
 
 
© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design